Table 1.

Metadata on the four patients in our cohort: sex, cystic fibrosis transmembrane conductance regulator (CFTR) mutation status, length of P. aeruginosa infection, clinical status, forced expiratory volume (% FEV1), modulator therapy, antibiotic treatment, and dominant infection strain type.

	Patent 1	Patent 2	Patent 3	Patent 4
Patient Sex	F	F	F	M
CFTR Mutation	F508del/R1162X	F508del/F508del	F508del/L467P	F508del/ 621+1G->T
Length of Pa infection	15 years, 2 months	12 years, 5 months	10 years, 4 months	13 years
Clinical status	APE Outpatient	APE Outpatient	Stable	APE Outpatient
FEV1 (%)	67.96%	74.92%	67.83%	60.30%
Modulator	None	None	None	None
Antibiotic Treatment	Inhaled tobramycin, oral azithromycin	Inhaled tobramycin, oral Trimethoprim / Sulfamethoxazole	Inhaled tobramycin, inhaled aztreonam, oral azithromycin	Inhaled tobramycin, oral Trimethoprim / Sulfamethoxazole, oral levofloxacin
Dominant ST	870	2999	1197	274